Results 1 to 10 of about 524,563 (211)

E.U. veterinary drug’s legislation [PDF]

open access: yesMedicamentul Veterinar, 2008
The paper makes a short intoduction in veterinary drug’s legislation and presents de functioning mechanisms of European Medicines Agency(EMEA). There are presented EMEA’s structure, responsabilities, EU topicdefinitions and other specific aspects.
Cristina, T. Romeo
doaj   +1 more source

Phytochemical and Nutraceutical Screening of Ethanol and Ethyl Acetate Phases of Romanian Galium verum Herba (Rubiaceae)

open access: yesMolecules, 2023
Galium species are used worldwide for their antioxidant, antibacterial, antifungal, and antiparasitic properties. Although this plant has demonstrated its antitumor properties on various types of cancer, its biological activity on cutaneous melanoma has ...
Alexandra-Denisa Semenescu   +8 more
doaj   +1 more source

Legislation and drug trials

open access: yesArchives of Disease in Childhood, 1997
Drugs used to treat children are often not licensed for use in this age group. Examples of licensed medicines used outside the conditions of the licence (‘off label’ usage) include the oral administration of a vitamin K injection preparation, and cisapride, which is commonly prescribed for infants, but is not licensed for children under 2 years of age.
D, Walsh, B, Drumm
openaire   +4 more sources

Doctor or drug dealer? International legal provisions for the legitimate handling of drugs of abuse [PDF]

open access: yes, 2020
© The Author(s) 2020. The final, definitive version of this paper has been published in: Gallagher, C. T., Atik, S. K., Isse, L., & Mann, S. K. (2020). Doctor or drug dealer?
Atik, Sanaa   +3 more
core   +2 more sources

Pricing of drugs and donations: options for sustainable equity pricing. [PDF]

open access: yes, 2001
Effective medicines exist to treat or alleviate many diseases which predominate in the developing world and cause high mortality and morbidity rates. Price should not be an obstacle preventing access to these medicines.
Ford, N, Herranz, E, Pérez-Casas, C
core   +2 more sources

Unrealized potential of drug repositioning in Europe during COVID-19 and beyond: a physician’s perspective

open access: yesJournal of Pharmaceutical Policy and Practice, 2020
Drug repositioning is the scientific strategy of investigating existing drugs for additional clinical indications. The advantages of drug repositioning are that it benefits patients and that it adds new indications to existing drugs for lower costs ...
A. B. Bayoumy   +4 more
doaj   +1 more source

Regulatory aspects of workplace drug testing in Europe. [PDF]

open access: yes, 2012
Workplace drug testing in Europe is governed by a patchwork of legislation – or lack of it. Other difficulties are caused by language, currency and a host of other factors, including the difficulty in defining ‘safety critical’.
Pierce, Anya
core   +1 more source

Subjective experiences of compulsory treatment from a qualitative study of early implementation of the Mental Health (Care and Treatment)(Scotland) Act 2003 [PDF]

open access: yes, 2013
Compulsory psychiatric treatment is highly contested, and little research has focused specifically on direct experiences. The Mental Health (Care & Treatment) (Scotland) Act, 2003 introduced new roles and provisions including community treatment orders,
Atkinson   +39 more
core   +1 more source

Update on dispensing Part II: Current Legislation

open access: yesSouth African Family Practice, 1989
No abstract available.
M.H. Cassimjee
doaj   +1 more source

Cannabis use prevalence among Baby Boomers before and after implementation of recreational retail sales in California

open access: yesSubstance Abuse Treatment, Prevention, and Policy, 2022
Background As of 2021, 21 US states and territories allowed recreational cannabis use. Although previous research has identified an overall increase in prevalence of cannabis use after legalization, it has been less clear how this change will affect ...
Zachary Carlson   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy